<DOC>
	<DOCNO>NCT01377428</DOCNO>
	<brief_summary>The study 12 week treatment ( 84 day ) , parallel group , randomize , double blind , double dummy , study assess superiority indacaterol ( 150 μg o.d . ) versus formoterol ( 12 μg b.i.d . ) term trough force expiratory volume 1 second ( FEV1 ) . Patients enrol give informed consent begin screening/run-in period 14 day . Patients randomize one two treatment group use allocation ratio 1:1 receive either indacaterol ( 150 μg o.d . ) placebo formoterol , formoterol ( 12 μg b.i.d . ) placebo indacaterol treatment period 12 week .</brief_summary>
	<brief_title>Efficacy Indacaterol 150 µg Versus Formoterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Diagnosis COPD ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2009 ) : Postbronchodilator FEV1 &lt; 80 % ≥40 % predict normal value Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Smoking history least 10 packyears Patients COPD exacerbation 6 week prior screen Patients respiratory tract infection within 6 week prior screen Patients concomitant pulmonary disease Patients history asthma Patients diabetes Type I uncontrolled diabetes Type II Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Indacaterol</keyword>
	<keyword>Formoterol</keyword>
</DOC>